دورية أكاديمية
أعرض في EDS

Ethyl pyruvate attenuates cellular adhesion and proliferation of diffuse large B-cell lymphoma by targeting c-Jun.

التفاصيل البيبلوغرافية
العنوان: Ethyl pyruvate attenuates cellular adhesion and proliferation of diffuse large B-cell lymphoma by targeting c-Jun.
المؤلفون: Yan Z, Zhong Q, Yan L; The First Affiliated Hospital of Gannan Medical University, Department of Ultrasonography, Ganzhou, 341000, China., Lai W; The First Affiliated Hospital of Gannan Medical University, Department of Hematology, Ganzhou, 341000, China., Xu X; The First Affiliated Hospital of Gannan Medical University, Department of Hematology, Ganzhou, 341000, China.
المصدر: Journal of applied biomedicine [J Appl Biomed] 2024 Jun; Vol. 22 (2), pp. 107-114. Date of Electronic Publication: 2024 Jun 20.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Sp z.o.o Country of Publication: Poland NLM ID: 101221755 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1214-0287 (Electronic) Linking ISSN: 1214021X NLM ISO Abbreviation: J Appl Biomed Subsets: MEDLINE
أسماء مطبوعة: Publication: <2013-> : Wroclaw : Elsevier Sp z.o.o.
Original Publication: České Budějovice, Czech Republic : University of South Bohemia, Faculty of Health and Social Studies
مواضيع طبية MeSH: Pyruvates*/pharmacology , Pyruvates*/therapeutic use , Lymphoma, Large B-Cell, Diffuse*/drug therapy , Lymphoma, Large B-Cell, Diffuse*/pathology , Cell Adhesion*/drug effects , Cell Proliferation*/drug effects, Humans ; Animals ; Cell Line, Tumor ; Mice ; Apoptosis/drug effects ; Proto-Oncogene Proteins c-jun/metabolism ; Proto-Oncogene Proteins c-jun/genetics ; Xenograft Model Antitumor Assays
مستخلص: Diffuse large B-cell lymphoma (DLBCL) stands out as the most common type of malignant cancer, representing the majority of cases of non-Hodgkin's lymphoma. Ethyl pyruvate (EP) is a derivative of pyruvic acid and found to have potent anti-tumor properties. Despite its potential benefits, the impact of EP on DLBCL remains ambiguous. Our objective is to elucidate the role of EP in modulating the development of DLBCL. Analysis of cholecystokinin-8 (CCK-8) revealed that treatment with EP significantly diminished the viability of DLBCL cells. Furthermore, EP administration suppressed colony formation and hindered cell adhesion and invasion in DLBCL cells. Examination of cell cycle progression showed that EP treatment induced arrest at the G1 phase and subsequently reduced the S phase population in DLBCL cells. EP treatment consistently exhibited apoptosis-inducing properties in Annexin-V assays, and notably downregulated the expression of Bcl-2 while increasing levels of proapoptotic cleaved caspase 3 and BAX in DLBCL cells. Additionally, EP treatment decreased the overexpression of c-Jun in c-Jun-transfected DLBCL cells. Further, EP demonstrated DNA-damaging effects in TUNEL assays. In vivo, xenograft animal models revealed that EP treatment significantly mitigated DLBCL tumor growth and suppressed DLBCL cell adhesion to bone marrow stromal cells. In summary, these findings suggest that EP mitigates DLBCL progression by inducing apoptosis, inducing cell cycle arrest, and promoting DNA damage.
Competing Interests: The authors report no conflicts of interest in this work.
References: Autio M, Leivonen SK, Brück O, Mustjoki S, Mészáros Jørgensen J, Karjalainen-Lindsberg ML, et al. (2021). Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma. Haematologica 106(3): 718-729. DOI: 10.3324/haematol.2019.243626. (PMID: 3207969010.3324/haematol.2019.243626)
Birkenmeier G, Hemdan NY, Kurz S, Bigl M, Pieroh P, Debebe T, et al. (2016). Ethyl Pyruvate Combats Human Leukemia Cells but Spares Normal Blood Cells. PloS One 11(8): e0161571. DOI: 10.1371/journal.pone.0161571. (PMID: 2757998510.1371/journal.pone.0161571)
Blonska M, Zhu Y, Chuang HH, You MJ, Kunkalla K, Vega F, Lin X (2015). Jun-regulated genes promote interaction of diffuse large B-cell lymphoma with the microenvironment. Blood 125(6): 981-991. DOI: 10.1182/blood-2014-04-568188. (PMID: 2553303310.1182/blood-2014-04-568188)
Cheng P, Dai W, Wang F, Lu J, Shen M, Chen K, et al. (2014). Ethyl pyruvate inhibits proliferation and induces apoptosis of hepatocellular carcinoma via regulation of the HMGB1-RAGE and AKT pathways. Biochem Biophys Res Commun 443(4): 1162-1168. DOI: 10.1016/j.bbrc.2013.12.064. (PMID: 2436189210.1016/j.bbrc.2013.12.064)
Cioroianu AI, Stinga PI, Sticlaru L, Cioplea MD, Nichita L, Popp C, Staniceanu F (2019). Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Role and Prognosis. Anal Cell Pathol (Amst) 2019: 8586354. DOI: 10.1155/2019/8586354. (PMID: 3193453310.1155/2019/8586354)
Crombie JL, Armand P (2020). Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: Genetic Classification and Its Implications for Prognosis and Treatment. Surg Oncol Clin N Am 29(1): 115-125. DOI: 10.1016/j.soc.2019.08.009. (PMID: 3175730810.1016/j.soc.2019.08.009)
Ennishi D, Hsi ED, Steidl C, Scott DW (2020). Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma. Cancer Discov 10(9): 1267-1281. DOI: 10.1158/2159-8290.CD-20-0174. (PMID: 10.1158/2159-8290.CD-20-0174)
Friedberg JW (2011). Relapsed/refractory diffuse large B-cell lymphoma. Hematology 2011(1): 498-505. DOI: 10.1182/asheducation-2011.1.498. (PMID: 2216008110.1182/asheducation-2011.1.498)
He W, Xu Z, Song D, Zhang H, Li B, Gao L, et al. (2020). Antitumor effects of rafoxanide in diffuse large B cell lymphoma via the PTEN/PI3K/Akt and JNK/c-Jun pathways. Life Sci 243: 117249. DOI: 10.1016/j.lfs.2019.117249. (PMID: 3192624710.1016/j.lfs.2019.117249)
Huang B, Lv D, Wang C, Shu F, Gong Z, Xie T, et al. (2018). Suppressed epithelial‑mesenchymal transition and cancer stem cell properties mediate the anti‑cancer effects of ethyl pyruvate via regulation of the AKT/nuclear factor‑κB pathway in prostate cancer cells. Oncol Lett 16(2): 2271-2278. DOI: 10.3892/ol.2018.8958. (PMID: 3000892910.3892/ol.2018.8958)
Huang Q, Fu Y, Zhang S, Zhang Y, Chen S, Zhang Z (2020). Ethyl pyruvate inhibits glioblastoma cells migration and invasion through modulation of NF-kappaB and ERK-mediated EMT. PeerJ 8: e9559. DOI: 10.7717/peerj.9559. eCollection 2020. (PMID: 3274281210.7717/peerj.9559)
Jingjing Z, Lei M, Jie Z, Sha C, Yapeng H, Weimin Z, Chunluan Y (2020). A novel MEF2C mutation in lymphoid neoplasm diffuse large B-cell lymphoma promotes tumorigenesis by increasing c-JUN expression. Naunyn Schmiedebergs Arch Pharmacol 393(8): 1549-1558. DOI: 10.1007/s00210-019-01764-6. (PMID: 3190051610.1007/s00210-019-01764-6)
Li ML, Wang XF, Tan ZJ, Dong P, Gu J, Lu JH, et al. (2012). Ethyl pyruvate administration suppresses growth and invasion of gallbladder cancer cells via downregulation of HMGB1-RAGE axis. Int J Immunopathol Pharmacol 25(4): 955-965. DOI: 10.1177/039463201202500413. (PMID: 2329848610.1177/039463201202500413)
Li S, Young KH, Medeiros LJ (2018). Diffuse large B-cell lymphoma. Pathology 50(1): 74-87. DOI: 10.1016/j.pathol.2017.09.006. (PMID: 2916702110.1016/j.pathol.2017.09.006)
Li Z, Zhu Y, Yu M, Ji D, Yang Z, Kong C (2013). c-Jun is involved in interstitial cystitis antiproliferative factor (APF)-induced growth inhibition of human bladder cancer T24 cells. Urol Oncol 31(2): 228-233. DOI: 10.1016/j.urolonc.2010.11.011. (PMID: 2187249810.1016/j.urolonc.2010.11.011)
Liang X, Romo Chavez AR, Schapiro NE, Loughran P, Thorne SH, Amoscato AA, et al. (2009). Ethyl pyruvate administration inhibits hepatic tumor growth. J Leukoc Biol 86(3): 599-607. DOI: 10.1189/jlb.0908578. (PMID: 1958431110.1189/jlb.0908578)
Liu Q, Huo Y, Zheng H, Zhao J, Jia L, Wang P (2019). Ethyl pyruvate suppresses the growth, invasion and migration and induces the apoptosis of nonsmall cell lung cancer cells via the HMGB1/RAGE axis and the NFkappaB/STAT3 pathway. Oncol Rep 42(2): 817-825. DOI: 10.3892/or.2019.7176. (PMID: 3117326510.3892/or.2019.7176)
Moro N, Sutton RL (2010). Beneficial effects of sodium or ethyl pyruvate after traumatic brain injury in the rat. Exp Neurol 225(2): 391-401. DOI: 10.1016/j.expneurol.2010.07.013. (PMID: 2067062410.1016/j.expneurol.2010.07.013)
Muller AJ, DuHadaway JB, Jaller D, Curtis P, Metz R, Prendergast GC (2010). Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate. Cancer Res 70(5): 1845-1853. DOI: 10.1158/0008-5472.CAN-09-3613. (PMID: 2016003210.1158/0008-5472.CAN-09-3613)
Ollila TA, Olszewski AJ (2018). Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence. Curr Treat Options Oncol 19(8): 38. DOI: 10.1007/s11864-018-0555-8. (PMID: 2993160510.1007/s11864-018-0555-8)
Park SY, Yi EY, Jung M, Lee YM, Kim YJ (2011). Ethyl pyruvate, an anti-inflammatory agent, inhibits tumor angiogenesis through inhibition of the NF-κB signaling pathway. Cancer Lett 303(2): 150-154. DOI: 10.1016/j.canlet.2010.12.024. (PMID: 2133343910.1016/j.canlet.2010.12.024)
Shen R, Xu PP, Wang N, Yi HM, Dong L, Fu D, et al. (2020). Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma. Clin Transl Med 10(7): e221. DOI: 10.1002/ctm2.221. (PMID: 3325285110.1002/ctm2.221)
Tsiambas E, Mastronikolis N, Fotiades PP, Kyrodimos E, Chrysovergis A, Papanikolaou V, et al. (2020). c-Jun/c-Fos complex in laryngeal squamous cell carcinoma. J Buon 25(2): 618-620.
Yang R, Zhu S, Tonnessen TI (2016). Ethyl pyruvate is a novel anti-inflammatory agent to treat multiple inflammatory organ injuries. J Inflamm (Lond) 13: 37. DOI: 10.1186/s12950-016-0144-1. (PMID: 2798045810.1186/s12950-016-0144-1)
Yu DH, Noh DH, Song RH, Park J (2010). Ethyl pyruvate downregulates tumor necrosis factor alpha and interleukin (IL)-6 and upregulates IL-10 in lipopolysaccharide-stimulated canine peripheral blood mononuclear cells. J Vet Med Sci 72(10): 1379-1381. DOI: 10.1292/jvms.09-0590. (PMID: 2049530110.1292/jvms.09-0590)
Yuen MF, Wu PC, Lai VC, Lau JY and Lai CL (2001). Expression of c-Myc, c-Fos, and c-jun in hepatocellular carcinoma. Cancer 91(1): 106-112. DOI: 10.1002/1097-0142(20010101)91:13.0.co;2-2. (PMID: 10.1002/1097-0142(20010101)91:13.0.co;2-2)
Zenz R, Scheuch H, Martin P, Frank C, Eferl R, Kenner L, et al. (2003). c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell 4(6): 879-889. DOI: 10.1016/s1534-5807(03)00161-8. (PMID: 1279127210.1016/s1534-5807(03)00161-8)
Zhang T, Guan XW, Gribben JG, Liu FT, Jia L (2019a). Blockade of HMGB1 signaling pathway by ethyl pyruvate inhibits tumor growth in diffuse large B-cell lymphoma. Cell Death Dis 10: 330. DOI: 10.1038/s41419-019-1563-8. (PMID: 3098827910.1038/s41419-019-1563-8)
Zhang Z, Yi P, Tu C, Zhan J, Jiang L, Zhang F (2019b). Curcumin Inhibits ERK/c-Jun Expressions and Phosphorylation against Endometrial Carcinoma. Biomed Res Int 2019: 8912961. DOI: 10.1155/2019/8912961. (PMID: 3208312210.1155/2019/8912961)
معلومات مُعتمدة: SKJP520201086-202130697 China Science and Technology Program of Jiangxi Provincial Health Commission
فهرسة مساهمة: Keywords: Adhesion; Diffuse large B cell lymphoma; Ethyl pyruvate; Proliferation; c-Jun
المشرفين على المادة: 03O98E01OB (ethyl pyruvate)
0 (Pyruvates)
0 (Proto-Oncogene Proteins c-jun)
تواريخ الأحداث: Date Created: 20240624 Date Completed: 20240624 Latest Revision: 20240624
رمز التحديث: 20240624
DOI: 10.32725/jab.2024.014
PMID: 38912866
قاعدة البيانات: MEDLINE
الوصف
تدمد:1214-0287
DOI:10.32725/jab.2024.014